Adicet Bio (FRA:1IJ) Valuation Rank


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €7.50
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Adicet Bio Valuation Rank Related Terms

FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.50
Price